Overview

RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT

Status:
Recruiting

Trial end date:
2021-09-01

Target enrollment:
0

Participant gender:
All

Summary

This study aimed to evaluate the efficacy of reduced intensity conditioning (RIC) regimen in elderly or high comorbidity burden patients who receive haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Haplo-HSCT is an effective treatment option for patients who did not have identical sibling donor (ISD) or unrelated donor (URD). However, post-transplant transplant-related mortality (TRM) is one of the major causes for transplant failure, and the risk of TRM for old patients or those with high comorbidity burden was higher. RIC regimen may decrease the risk of TRM for haplo-HSCT recipients. The study hypothesis: Using RIC haplo-HSCT regimen in elderly patients or those with high comorbidity burden can reduce TRM and improve survival.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Peking University People's Hospital

Treatments:

Antilymphocyte Serum
Busulfan
Cyclophosphamide
Cytarabine
Fludarabine
Fludarabine phosphate
Semustine
Thymoglobulin

Criteria

Inclusion Criteria:

- Patients older than 55 years or those with HCT-CI scores of ≥3, without ISD nor URD,
receiving haplo-HSCT

Exclusion Criteria:

- patients having identical sibling or unrelated donors; patients with active infection;
patients having organ failure; patients with poor compliance.